{"Symbol": "ADXS", "AssetType": "Common Stock", "Name": "Advaxis, Inc", "Description": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "305 College Road East, Princeton, NJ, United States, 08540", "FullTimeEmployees": "35", "FiscalYearEnd": "October", "LatestQuarter": "2020-04-30", "MarketCapitalization": "33327178", "EBITDA": "-26629000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.588", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-4.094", "RevenuePerShareTTM": "0.006", "ProfitMargin": "0", "OperatingMarginTTM": "-124.3423", "ReturnOnAssetsTTM": "-0.4255", "ReturnOnEquityTTM": "-0.8708", "RevenueTTM": "260000", "GrossProfitTTM": "20884000", "DilutedEPSTTM": "-0.842", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.79", "AnalystTargetPrice": "5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "74.7309", "PriceToBookRatio": "0.8463", "EVToRevenue": "31.5874", "EVToEBITDA": "0", "Beta": "3.511", "52WeekHigh": "1.48", "52WeekLow": "0.2051", "50DayMovingAverage": "0.5471", "200DayMovingAverage": "0.6562", "SharesOutstanding": "62715800", "SharesFloat": "48230726", "SharesShort": "1548454", "SharesShortPriorMonth": "1484941", "ShortRatio": "1.48", "ShortPercentOutstanding": "0.02", "ShortPercentFloat": "0.0228", "PercentInsiders": "0.47", "PercentInstitutions": "19.356", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:15", "LastSplitDate": "2019-03-29"}